Intraoperative hypercoagulability during liver transplantation as demonstrated by thromboelastography

Dominik Krzanicki, Anita Sugavanam, Susan Mallett – 21 May 2013 – Thrombotic complications are more common in liver disease than might be expected because of the coagulopathy described by conventional coagulation tests. Some of these complications may be life‐threatening. The phenomenon of hypercoagulation is associated with complications in many populations, but the incidence in liver transplant recipients is unclear. We performed a retrospective database review of intraoperative thromboelastography (TEG) for 124 liver transplant recipients.

Chronic Lithium Treatment Protects Against Liver Ischemia/Reperfusion Injury in Rats

Anding Liu, Haoshu Fang, Uta Dahmen, Olaf Dirsch – 21 May 2013 – Lithium has long been widely used in the treatment of bipolar mood disorders. Recent studies have demonstrated that lithium is able to decrease ischemia/reperfusion (I/R) injury in the brain, kidneys, and heart. Because lithium may act on a number of stress and survival pathways, it is of great interest to explore this compound also in the setting of liver I/R injury. In this study, we aimed to evaluate the effects of lithium in a model of liver I/R injury in rats.

Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation

Surakit Pungpapong, Bashar A. Aqel, Ludi Koning, Jennifer L. Murphy, Tanisha M. Henry, Kristen L. Ryland, Maria L. Yataco, Raj Satyanarayana, Barry G. Rosser, Hugo E. Vargas, Michael R. Charlton, Andrew P. Keaveny – 21 May 2013 – The safety, efficacy, and effect on immunosuppression levels of telaprevir (TVR) or boceprevir (BOC) in combination with peginterferon (PEG‐IFN) and ribavirin (RBV) in recipients of liver transplantation (LT) with hepatitis C virus (HCV) genotype 1 have not been defined.

Lipocalin‐2 negatively modulates the epithelial‐to‐mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF‐beta1)/Lcn2/Twist1 pathway

Yun‐Peng Wang, Goung‐Ran Yu, Mi‐Jin Lee, Sang‐Yeop Lee, In‐Sun Chu, Sun‐Hee Leem, Dae‐Ghon Kim – 20 May 2013 – Lipocalin‐2 (Lcn2) is preferentially expressed in hepatocellular carcinoma (HCC). However, the functional role of Lcn2 in HCC progression is still poorly understood, particularly with respect to its involvement in invasion and metastasis. The purpose of this study was to investigate whether Lcn2 is associated with the epithelial‐mesenchymal transition (EMT) in HCC and to elucidate the underlying signaling pathway(s).

Subscribe to